A series of inductive events between two dierent cell groups, the ureteric bud epithelium and metanephric mesenchyme, gives rise to the functional mammalian kidney. These reciprocal inductive interactions involve a number of molecules, one of which is the RET receptor tyrosine kinase. The phenotype of mice lacking functional RET includes kidney agenesis or severe dysgenesis, indicating a requirement for RET in kidney organogenesis. To investigate RET expression in human kidney development, we used a semi-quantitative RT ± PCR-based strategy to examine a panel of kidney RNA samples ranging from 8 ± 24 weeks gestational age. We found RET expression was highest earlier in development (14 weeks) with expression decreasing through to 24 weeks gestation. While three alternative RET transcripts generated by exon skipping at the 5' end of the gene were all detected throughout kidney development, expression of one transcript, RET2/6, where exon 2 was spliced to exon 6, varied relative to full length RET during this period. Levels of RET2/6 were highest at the earliest age of fetal kidney examined (8 weeks) and decreased relative to all other RET transcripts to low adult levels. The period of high expression coincides with a period of rapid bud bifurcation. Thus, it is possible that RET2/6 has a role in the early growth and dierentiation of the human kidney.
Introduction
The mammalian kidney develops through a series of reciprocal inductive interactions between two cell groups that share a common mesodermal origin: ureteric bud epithelium and metanephric mesenchyme (Saxen, 1987) . Upon induction, the ureteric bud, an outgrowth of the Wolan duct, grows and branches repeatedly to produce the collecting duct system of the kidney while undierentiated metanephric mesenchyme condenses and epithelializes, forming glomeruli and proximal and distal convoluted tubules. A number of molecules, including WT-1 (Kreidberg et al., 1993) , WNT-4 (Stark et al., 1994) and Pax-2 (Rothenpieler and Dressler, 1993) and members of the Hox family (reviewed in Bard et al., 1994) , have been implicated in induction of these dierentiating events, the precise nature of which remains to be clari®ed. Recent studies have suggested that the RET proto-oncogene may also be essential to these processes. RET encodes a receptor tyrosine kinase with roles in migration, development and survival of neural crest cells and their derivatives (Pachnis et al., 1993; Avantaggiato et al., 1994; Nakamura et al., 1994; Tsuzuki et al., 1995) . Multiple RET transcripts, generated by alternative splicing of RET exons encoding the extracellular ligand-binding and C-terminal domains, are expressed in cells and tissues derived from the neural crest, branchial arches and ureteric bud (Tahira et al., 1990; Pachnis et al., 1993; Lorenzo et al., 1995) .
Several pieces of evidence have suggested the involvement of RET in kidney induction. First, in situ hybridization studies in murine embryos have identi®ed RET expression in the kidney as early as 8.5 days post coitum (d.p.c.) with highest levels in that portion of the Wolan duct that will evaginate to produce the ureteric bud (Pachnis et al., 1993) . RET expression is later localized to the ureteric bud epithelium and the branching tips of the bud. Levels of RET peak at 11.5 d.p.c., then decrease with time. Second, the phenotype of the RET knockout mouse (RET7/7) indicates that RET is essential to kidney development. RET7/7 mice display kidney agenesis or severe dysgenesis characterized by reduced branching of the ureteric bud, absence of a mature collecting tubule system and large areas of undierentiated mesenchyme (Schuchardt et al., 1994) . Third, ureteric bud tissue from RET+/+ mice is able to grow and branch in culture in the presence of RET+/+ or 7/7 metanephric mesenchymal tissue. However, ureteric bud tissue from RET7/7 mice fails to branch in the presence of either RET7/7 or RET+/+ mesenchyme suggesting that the RET7/7 bud is unable to transduce a mesenchyme-derived signal (Schuchardt et al., 1994 . Finally, several recent studies have identi®ed a ligand for RET which is also implicated in kidney morphogenesis. The RET ligand is a multimeric complex composed of glial cell line-derived neurotrophic factor (GDNF), a soluble molecule, and GDNF receptor-a (GDNFR-a), a glycosyl-phosphatidylinositol (GPI)-linked cell surface receptor without an intracellular domain which must interact with RET to transduce signals intracellularly (Treanor et al., 1996; Jing et al., 1996) . GDNF7/7 mice have similar phenotypic characteristics to their RET7/7 counterparts: kidney agenesis or severe dysgenesis and absence of the enteric ganglia (SaÂ nchez et al., 1996; Moore et al., 1996; Pichel et al., 1996) . Consistent with RET's proposed role as a transducer of mesenchyme-derived signals in kidney induction, GDNF expression has been localized to the metanephric mesenchyme (Hellmich et al., 1996) .
Although murine studies have suggested developmental regulation of RET in kidney organogenesis, the expression of RET in human kidney development has not been investigated. In this study, we examined RET expression in a panel of human fetal kidney RNAs using semi-quantitative reverse transcription-polymerase chain reaction (RT ± PCR). We have found that RET expression is developmentally regulated with highest expression in the earliest gestational ages decreasing with time and with lowest levels of RET being detected in adult kidney. In addition, we have shown that the developmental expression patterns are dissimilar amongst the various RET alternative transcripts. Our data suggest that an alternatively spliced form of RET, which encodes a product lacking a portion of the extracellular ligand-binding domain (Figure 1 ), has a higher prevalence and perhaps a greater signi®cance, in the earliest developmental stages of the human kidney.
Results

RET expression in human kidney development
We examined the expression of RET in a panel of RNAs from human fetal kidneys ranging in gestational age from 8 to 24 weeks and from adult kidney. RNA from medullary thyroid carcinoma cell line TT, known to express RET at high levels, was used as a positive control (Leong et al., 1983; Santoro et al., 1990) . Owing to limited quantities of RNA available for analysis, RT ± PCR was used to investigate RET expression. Initial analyses were conducted using primers CRT17S and CRT17A which amplify RET exon 15 (2757 ± 2778 bp), within the RET tyrosine kinase domain (Takahashi et al., 1988) . This 122 bp amplicon is present in all transmembrane RET isoforms and would thus serve as an indicator of overall RET expression. RT ± PCR of total RNA identi®ed an ampli®cation product of the predicted size for all ages of fetal kidney examined as well as for adult kidney and the TT cell line (data not shown). Initial inspection suggested that the level of RET ampli®cation for adult kidney was relatively lower than the levels observed for our fetal kidney samples and the TT cell line, suggesting a developmentally regulated RET expression pattern. This is consistent with previous mouse and rat studies which showed that levels of RET expression decrease with time during kidney development (Tahira et al., 1988; Pachnis et al., 1993; Avantaggiato et al., 1994; Tsuzuki et al., 1995) .
Quantitation of RET expression during human kidney development
To investigate relative RET expression levels during human kidney organogenesis, we developed a semiquantitative RT ± PCR assay that compared relative expression levels of RET and a housekeeping gene, bglucuronidase (GUSB), in a given RNA sample using multiplex PCR. Comparisons of relative levels of expression were used in preference to comparison to an external standard in order to eliminate variations due to inter-sample dierences in RNA quality. Previous studies have shown that GUSB is expressed at consistent levels throughout kidney development (Bracey and Paigen, 1987; Bevilacqua et al., 1988) . PCR was performed with primers CRT17S and CRT17A to amplify RET and GUSB3 and GUSB5 to amplify a GUSB product of 195 bp (530 ± 725 bp). A 10 : 1 molar ratio of RET primers to GUSB primers proved to be optimal for co-ampli®cation of both products. PCR ampli®cation proceeds exponentially; therefore, for reliable quantitation of product, PCR conditions must be selected so that quantitation is performed in the linear phase of ampli®cation, where concentrations of product are proportional to starting levels of target (Morrison and Gannon, 1994) . Experiments were conducted to determine the kinetics of ampli®cation over a range of cycle numbers to select conditions for which ampli®cation was linear. Endlabeled forward primers were included in PCRs and the quantity of PCR product was represented by the amount of radioactive incorporation. Template cDNAs were ampli®ed for 12, 16, 20, 24, 28, 32 or 36 cycles. The relevant products were quantitated by separation on 2% agarose gels, excision of the appropriate bands and measurement of incorporated counts (c.p.m.). We found that ampli®cation was linear for both GUSB and RET between 18 and 26 cycles (Figure 2a ). To ensure that ampli®cation occurred with equal eciency regardless of amount of starting template, we performed PCR using a two-fold serial dilution of TT cDNA for 22, 25 or 26 cycles. A linear relationship between input cDNA and amount of PCR product was identi®ed for each of GUSB and RET when PCR proceeded for 25 cycles (Figure 2b ).
In our initial analyses, we chose to investigate RET expression in four kidney RNA samples that spanned the range of gestational ages available: 14-, 18-and 24-weeks gestation as well as adult kidney. The reliability of the conditions established for quantitation of transcripts in the TT cell line was con®rmed for kidney samples. Quantitation of RET expression relative to GUSB expression during human kidney development was performed at 25 cycles of PCR. Semi-quantitative PCR assays were repeated ®ve times for each of 14-, 18-and 24-week human fetal kidney samples as well as for human adult kidney and mean expression with standard deviation calculated. The expression of RET relative to GUSB was assessed by comparison of incorporated counts, where RET product was expressed as a fraction of GUSB product (Table 1) . RET expression levels were highest in the 14-week kidney but 1.5-fold lower by 18 weeks. RET expression was only slightly lower in 24-week kidney, diering from expression in 18-week kidney by about 2%. The level of RET expression in adult kidney was 1.2-fold lower than that in 24-week kidney and almost two-fold lower compared to 18-week kidney. Thus, RET expression appeared to decrease with increasing gestational age.
RET alternative splice variants
Our initial analyses indicated that RET was expressed in a developmentally regulated fashion in the human kidney. Although this may re¯ect overall reduction in RET expression, it could equally represent dierences in expression of the many RET mRNA forms generated by dierential splicing. Alternative RET transcripts in which exon 2 may be juxtaposed to any of exons 3, 4, 5 or 6, resulting in a shorter putative RET ligand binding domain, have been reported ( Figure 1 ; Lorenzo et al., 1995) . Using the sample panel described above, we investigated the expression of these variant RET transcripts during human kidney development. In order to distinguish the various RET mRNAs generated by alternative splicing of RET 5' exons, RT ± PCR analyses were conducted using primer combinations that ampli®ed each independently and exclusively ( Figure 3 ). Speci®city was ensured by using a forward primer that spanned the splice junction of exon 2 and the downstream exon and a reverse primer within the downstream exon. Amplicons predicted for full length (FL) transcript and those lacking exon 3 (2/ 4), exons 3 and 4 (2/5) and exons 3, 4 and 5 (2/6) were 210 bp, 262 bp, 196 bp and 148 bp, respectively.
PCR ampli®cation speci®c for each transcript was performed using the panel of fetal and adult kidney samples described above. Products were resolved on agarose gels, Southern blotted and probed with an end-labeled oligonucleotide speci®c for the 3' exon present in each ampli®ed product. A single PCR product corresponding to each of the predicted sizes was observed in all samples of fetal and adult kidney indicating that each RET 5' spliced variant is expressed from 8 weeks through 24 weeks gestation (Figure 3 ).
Quantitation of RET alternative splice variants
We addressed the possibility of variation in expression of RET 5' alternative splice variants using a semiquantitative RT ± PCR assay similar to that described above. We compared the expression level of each RET alternative transcript to that of FL RET in our panel of human kidney RNA by pairwise ampli®cations using three primers in each reaction: a single forward primer in exon 2 (X2S) and two reverse primers, one in exon 3 (CRT7A) and the other in one of exons 4 (X4A), 5 (E5A) or 6 (E6A). In combination with a forward primer in exon 2, the latter primers would amplify alternative splice variants 2/4, 2/5 and 2/6 respectively. Although, in theory, the forward primer and any of the reverse primers would amplify full length transcripts as well, these longer products were not detected. Amounts of RET and GUSB product ampli®ed in a single multiplex reaction were quantitated by liquid scintillation counting of radioactivity incorporated in PCR products which had been resolved on 2% agarose gels and excised. Counts (measured in c.p.m.) were plotted relative to the number of ampli®cation cycles. The exponential reaction phase was linear between 18 and 26 cycles. Above 26 cycles, rates of ampli®cation for both RET and GUSB products decreased and approached plateau. (b) Con®rmation of ampli®cation eciencies of RET and GUSB primers used in multiplex PCR. A two-fold serial dilution of TT cDNA was subjected to 22, 25 or 26 cycles of PCR. The results for 25 cycles are shown. Linear results were obtained when counts were plotted relative to dilution factor for ampli®cation of both RET and GUSB transcripts. Similar slopes for the linear plots indicate comparable ampli®cation eciencies for these primer pairs
As described above, optimal RT ± PCR conditions for comparison of expression of the dierent RET transcripts were chosen based on experiments which de®ned the linear range of ampli®cation. Ampli®cation was found to be linear between 22 and 30 cycles for all primer combinations (data not shown). Quantitative PCR analyses were performed at 28 cycles of ampli®cation which was both within the linear range for all primer combinations and permitted visualization of even the least abundant transcript upon electrophoresis. To ensure that ampli®cation occurred with equal eciency regardless of amount of starting template, we performed PCR using two-fold serial dilutions of 14-, 18-and 24-week human fetal kidney samples as well as adult kidney and TT cell line cDNAs.
Initially, we investigated RET expression in RNA samples from 14-, 18-and 24-week as well as adult kidney. RT ± PCR experiments were performed at 28 cycles of ampli®cation and the expression levels of alternative RET transcripts were calculated as fractions of FL RET. Quantitation of each alternative RET transcript in a sample was performed twice for each of three independent cDNA preparations and the data summarized in Table 2 . We found that FL RET was the most highly expressed RET transcript in each sample analysed. The expression levels of the RET2/4 and RET2/5 transcripts were both much lower than those of FL RET. These transcripts maintained a level of expression approximately 1/3 that of FL RET at all stages of development.
The RET2/6 transcript was the least abundant transcript in all samples tested, being expressed at 0.22+0.02 times the levels of FL RET in 14-week kidney and at lower levels in 18-week (0.18+0.02) and 24-week kidney (0.14+0.03) (Table 2, Figure 4a) . In adult kidney, the expression level of RET2/6 was approximately 1/6 that of FL RET. Our data suggested that expression of the RET2/6 transcript was higher in earlier stages of human kidney development relative to other RET 5' splice variants and decreased more rapidly through to 24 weeks gestation. Figure 3 Expression of RET transcripts generated by alternative splicing at the 5' end of the gene in human fetal kidney and adult kidney detected by RT ± PCR analyses. PCR ampli®cation of the four RET mRNA forms was conducted using primer pairs described in Materials and methods. The predicted ampli®cation product for each, as well as the exon location of the primers used to amplify the speci®c products, are indicated. PCR products were resolved on 2% agarose gels, Southern blotted and membranes hybridized to a labelled primer corresponding to the 3' exon. A positive control (the TT cell line) and a negative control (H 2 O only) are indicated
In order to con®rm this observation, we compared the expression of FL RET and RET2/6 in our full panel of human fetal kidney RNAs. The expression level of the RET2/6 transcript relative to FL RET was calculated as described above. We found that RET2/6 was expressed at higher levels in the earliest gestational ages of human kidney we examined (0.26+0.02 in 8-week kidney), approaching the relative expression of RET2/4 and RET2/5 seen throughout our tested samples (0.15+0.02 in 24-week and 0.14+0.02 in adult kidney) (Table 3, Figure 4b ).
Discussion
The mature metanephric kidney arises from inductive interactions between epithelial (ureteric bud) and mesenchymal (metanephric mesenchyme) cells. It is clear that this complex process involves a number of biochemical signals rather than a single molecular event. The RET receptor tyrosine kinase and members of its ligand complex, GDNF and GDNFR-a, are likely to play roles in both kidney induction and morphogenesis. Using semi-quantitative RT ± PCR methodology, we have shown that RET is expressed in human fetal kidney during the 8 to 24 week period of gestation. Further, RET expression is highest early in development but decreases through to 24 weeks gestation relative to expression of a housekeeping gene control. This is consistent with the RET expression pattern observed in mice and rats where RET expression has been localized to the ureteric bud in early kidney development but later appears in the actively growing tips of the bud branches (Tsuzuki et al., 1995; Avantaggiato et al., 1994; Pachnis et al., 1993) . The relatively high RET expression level early in development coincides with a stage of kidney morphogenesis in which the ureteric bud undergoes rapid bifurcation. This process of rapid branching is initiated at 8 weeks and continues until 14 ± 15 weeks when the rate of branching slows. During this period, cells of the metanephric mesenchyme condense, epithelialize and begin to dierentiate to form the nephrons while the ureteric bud continues to branch and the bud cells proliferate (reviewed in Potter, 1972) . While the ureteric bud is active from the time of its development through to 36 weeks intrauterine life, the role of the bud varies during the process of kidney development. During this period, the bud induces condensation and epithelialization of the surrounding mesenchyme, resulting in nephrons which attach to tubules that form within the zone of bud growth. Branching seldom occurs between 20 and 32 weeks. Given the relatively higher expression of RET we observed in 14-week human fetal kidney compared to Figure 4 Developmental expression of splice variants generated by alternative splicing at the 5' end of RET in human fetal kidney.
(a) Levels of alternatively spliced RET transcripts at three gestational ages relative to expression of the FL RET transcript ampli®ed in the same multiplex RT ± PCR reaction for a given sample. Quantitation was performed as in Figure 3 . Mean values shown in Table 2 are plotted. (b) Pro®le of developmental expression of RET2/6 transcript generated by splicing exon 2 to exon 6. Expression levels of RET2/6 were calculated as fractions of FL RET as described above. Mean values from Table 3 are plotted   Table 3 Quantitation of RET2/6 relative to FL RET based on multiplex RT ± PCR analyses. Means were calculated based on six individual repeats of the assay. Data also reported in Table 2 24-week fetal kidney, it is possible that RET's signi®cance changes according to the stage of renal development. In the context of this expression pattern, however, it is noteworthy that clinically signi®cant kidney abnormalities are not observed in individuals with known RET mutations (reviewed in Eng and Mulligan, 1997) . While the RET expression pattern suggests a more signi®cant involvement of RET in earlier developmental stages, whether it functions in cell dierentiation, proliferation or both requires further investigation. The developmentally regulated pattern of RET expression in human kidney suggests that RET may have varying roles or signi®cance at dierent stages of kidney development. It is possible that this eect is simply mediated by the relative level of overall RET expression. However, it is also possible that dierences in expression of the various RET alternatively spliced transcripts aect RET's contribution to the process of kidney development. Multiple isoforms of RET arise as a result of alternative splicing events (Tahira et al., 1990; Lorenzo et al., 1995; Myers et al., 1995) . These RET isoforms may have dierent roles in human renal development, perhaps by recognizing dierent RET ligands or binding the same ligand with dierent anities. We have shown that all RET 5' spliced variants are expressed in the human kidney throughout the 8-to 24-week gestational period but that the relative levels of these alternative RET forms vary (Figure 4a ). FL RET was most abundant in all samples while RET2/4 and RET2/5 transcript expression levels were consistently about 1/3 that of FL RET. Interestingly, however, RET2/6 expression levels varied with respect to all other RET splice forms, being relatively more abundant in early kidney developmental stages (0.26+0.02 in 8-week) and decreasing more markedly to low adult levels (0.15+0.02) (Figure 4b) .
Although all RET mRNA forms are expressed at relatively high levels during early kidney development and decrease with time, the variation in RET2/6 expression is most striking. In neural crest-derived cells, RET is predicted to function in both differentiation and proliferation processes. Activated forms of RET have the ability to induce dierentiation in PC12 cells (Bunone et al., 1995; Asai et al., 1995; Califano et al., 1995) . In contrast, activated RET is transforming in NIH3T3 cells, resulting in proliferation Califano et al., 1995; Santoro et al., 1993) . In human kidney, it is not clear which role is chie¯y attributable to RET. However, it is conceivable that dierent RET isoforms may have dierent roles. Lorenzo et al. (1995) examined the relative levels of RET 5' alternatively spliced transcripts in a panel of tumours of neural crest origin. In these analyses, RET2/6 expression was approximately 1/10 FL RET expression, similar to the expression levels we detected in adult kidney. Our data show that the high expression level of RET2/6 coincides with the period of rapid bud bifurcation and growth of the ureteric bud. If RET2/6 was simply a marker of rapidly dividing cells, we would expect to see similar levels of this transcript in developing fetal kidney and tumours. However, our data suggest that levels of RET2/6 are comparable in neural crest-derived tumours and cell lines and in human adult kidney, tissues with very dierent proliferative pro®les. In fact, RET2/6 was 2.5-fold more abundant in 8-week human fetal kidney than in either human adult kidney or the TT cell line. These data suggest that the RET2/6 product may have a non-proliferative role in human kidney morphogenesis.
Many receptor tyrosine kinases generate multiple isoforms by alternative splicing. When such events occur near the 5' end of the gene, ligand-binding domains may be aected resulting in altered ligandbinding speci®cities. In the case of ®broblast growth factor receptor type 2, for example, alternative exon usage in the immunoglobulin-like loop region results in receptor variants with dierent ligand-binding anities (Miki et al., 1992; Yayon et al., 1992) . These transcripts are expressed in a tissue-and developmental stage-speci®c fashion (Orr-Urtreger et al., 1993; McDonald, 1994; Shi et al., 1994) . The relatively high expression of RET2/6 in early human renal development may suggest a requirement for this speci®c RET isoform during that time. The RET2/6 transcript encodes a molecule that lacks 239 amino acids spanning four potential N-glycosylation sites, seven cysteine residues and the region of cadherin homology, which are all present in FL RET (Figure 1 ). Ligand binding is thought to involve all or part of this region (Takahashi et al., 1988) . Given the decreased length of this region in RET2/6, it is possible that this molecule binds a dierent ligand than its full length counterpart or that it binds the same ligand with dierential anity. At present, the expression of the RET2/6 protein isoform has not yet been established in vivo although in vitro translation of the RET2/6 transcript has been described (Lorenzo et al., 1995) .
Recently, the RET ligand was identi®ed as a novel form of multicomponent ligand complex, consisting of GDNF and GDNFR-a (Treanor et al., 1996; Jing et al., 1996) . GDNF is a soluble molecule which forms disul®de-linked dimers that bind to a novel GPI-linked protein, GDNFR-a. The GDNF/GDNFR-a complex then binds to RET which dimerizes, resulting in autophosphorylation and downstream signaling (Jing et al., 1996) . We have identi®ed expression of both GDNF and GDNFR-a in human fetal kidney ranging in gestational age from 8 to 24 weeks (data not shown). Expression of these transcripts during kidney development is consistent with their role as RET ligands. The phenotype of RET7/7 and GDNF7/7 mice and in vitro explant studies have clearly shown that both RET and GDNF are required for inductive events during kidney development. Interestingly, the dierences in phenotype between RET7/7 and GDNF7/7 mice have suggested that another RET ligand may exist. In RET7/7 mice, the superior cervical ganglion neurons are absent (Schuchardt et al., 1994; Durbec et al., 1996) , while they are only moderately reduced in GDNF7/7 mice (SaÂ nchez et al., 1996; Moore et al., 1996; Pichel et al., 1996) . In other respects, these mice have very similar phenotypes. The RET2/6 transcript is predicted to encode a molecule that diers from its full length counterpart in that it lacks a portion of the protein thought to be involved in ligand-binding. Thus, RET2/6 is a logical candidate as a receptor for an alternative ligand.
Our data have shown that multiple RET 5' splicing variants are expressed in a developmentally regulated fashion during human kidney development (Figure 4) . The relatively high expression levels and clear developmental dierences in expression of these variants suggest that they represent functional isoforms and not tolerated artifacts of splicing. Interestingly, RET2/6, the RET isoform with the shortest extracellular domain, had the strongest developmental variation in expression. RET2/6 lacks part of the predicted region of ligand binding present in FL RET which raises the possibility that it interacts with a dierent ligand with relevance in mammalian kidney development. Thus, metanephric kidney formation may be dependent on more than one role for RET: the RET/GDNF/GDNFR-a interaction and another as yet uncharacterized signaling molecule.
Materials and methods
Growth of TT cells
The medullary thyroid carcinoma cell line TT was grown at 378C in humidi®ed air in L-15 medium (Gibco-BRL Life Technologies) supplemented with 10% fetal calf serum (Wisent) and gentamycin (50 mg/ml). Cells were grown as monolayers and replated weekly.
RNA extraction
Total RNA was isolated from TT cells using the TRIzol method according to manufacturer's instructions (Gibco-BRL Life Technologies). Total RNA was isolated from adult kidney tissue and fetal kidney tissue ranging in gestational age from 8 weeks to 24 weeks essentially by the method of Chomczynski and Sacchi (1987) .
Fetal kidney, adult kidney and TT RNA analyses
One mg of total RNA was heated at 708C for 5 min and cooled on ice brie¯y. First strand cDNA was generated from these templates by incubating in 50 mM Tris-HCl (pH 8.3), 8 mM MgCl 2 , 30 mM KCl, 10 mM dithiothreitol (DTT), 2 mM deoxynucleoside triphosphates (dNTPs), 7 units AMV reverse transcriptase (Promega), 10 units human placental RNase inhibitor (Pharmacia) and either 2 mM random hexamer primers (Pharmacia) or 2 mM oligo dT 15 primer (GENOSYS) at 428C for 1 h. To inactivate the enzyme, samples were incubated at 658C for 10 min and then frozen at 7208C. PCR ampli®cation of cDNA templates was performed in 10 mM Tris-HCl (pH 8.3), 50 mM KCl, 0.01% gelatin, 1 mM of each primer, 200 mM dNTPs and 1.5 units Taq DNA polymerase (Gibco-BRL Life Technologies) with 0.75 ± 1.5 mM MgCl 2 depending on primers being used. Unless otherwise stated, PCR ampli®cation was carried out for 40 cycles of 958C 1 min/558C 1 min/728C 1 min.
Primer sequences
RET speci®c primers used in these analyses were as follows: CRT17S and CRT17A (exon 15); p23F (exon 2/ 3) and CRT7A (exon 3); p24F (exon 2/4) and CRT8A (exon 4); p25F (exon 2/5) and E5A (exon 5); and p26F (exon 2/6) and E6A (exon 6) Kwok et al., 1993; Lorenzo et al., 1995) . Additional RET primers used in quantitation experiments were X2S (5'-GCCTCCTCTACCTTAACCGGA-3') and X4A (5'-GGAAGGTGGGCGCCGAGTCG-3'). Primers speci®c for the b-glucuronidase gene were GUSB3 (5'-AC-TATCGCCATCAACAACACACTCACC-3') and GUSB5 (5'-GACGGTGATGTCATCGATGT-3').
Semi-quantitative PCR
For quantitation experiments, RT ± PCR was performed in 10 mL volumes using the PCR conditions described above but including 0.1 mM 32 P-end-labeled sense strand primers and varying the amounts of cold primers used and MgCl 2 buer concentrations. Speci®cally, in multiplex PCR to amplify RET and GUSB products, 1 mM RET primers (CRT17S, CRT17A) and 0.1 mM GUSB primers (GUSB3, GUSB5) were used in 1.5 mM MgCl 2 buer conditions. To amplify the RET alternative splice variants, 1 mM concentrations of all primers were used in pairwise ampli®cation experiments (CRT7A/X2S/X4A, CRT7A/X2S/E5A, CRT7A/X2S/E6A) in buer containing 0.75 mM MgCl 2 . Analyses to determine the linear range of ampli®cation were performed using 1/10 of a cDNA reaction as described above in PCR for 12, 16, 20, 24, 28, 32 or 36 cycles. PCR products were separated on 2% agarose gels and appropriate bands were excised. Quantitation of PCR products was determined by liquid scintillation of incorporated radioactivity. Plots of incorporated counts (c.p.m.) versus cycle number were examined to de®ne the range of PCR cycle numbers for which ampli®cation was linear (Figure 2a) . Two-fold serial dilutions of cDNA were subjected to cycles of PCR within the linear range to con®rm the number of cycles which would amplify with similar eciency regardless of amount of starting template. PCR products were separated on 2% agarose gels, appropriate bands were excised and liquid scintillation counting was used to measure incorporated radioactivity (measured in c.p.m.). If the relationship of c.p.m. versus dilution factor was linear, the conditions were considered reliable for quantitation purposes (Figure 2b ). For quantitation of RET relative to GUSB, 25 cycles was chosen for all further studies while for quantitation of RET alternative splice variants relative to FL RET, 28 cycles was used for all further experimentation.
Southern blotting
PCR products were resolved on 2% agarose gels and transferred to Hybond N + membranes (Amersham). Oligonucleotide probes were labelled in a reaction containing 30 mCi [g 32 P]-ATP, 10 units of T4 polynucleotide kinase (Gibco-BRL Life Technologies), 50 mM Tris-HCl (pH 7.6), 10 mM MgCl 2 , 5 mM DTT, 100 mM spermidine-HCl, 100 mM EDTA (pH 8.0) at 378C for 30 min. Probes were ethanol precipitated prior to use. Blots were prehybridized and hybridized at 378C as described in Lorenzo et al. (1995) and washed in 0.16SSC/0.1% SDS at 658C.
